For personal use only

IDT Greatly Expands Generics Production Capacity with New Manufacturing Partner

Complement IDT Manufacturing Skills and Facilities

Increases IDT Products' Speed to Market and Revenues

Doubles resources for IDT's Generics Range

30 March, 2016, Melbourne: IDT Australia Limited (IDT.AX) has concluded a manufacturing and supply agreement with WellSpring Pharma Services Inc of Oakville, Ontario, Canada. WellSpring will manufacture an initial group of two to three products that require manufacturing processes or scale not currently available at IDT's Boronia facilities. The first product being worked on by WellSpring is pindolol, a cardiac drug with an addressable US market of US$10m (2015). The product has low levels of competition and high margins.

Placing these products in a second facility doubles the resources being applied to the re-commercialization of IDT's proprietary generics range and accelerates progress towards revenues and profitability from our own range of products.

Wellspring has been inspected by IDT and commenced work on the products under an initial works order in late 2015. IDT-WellSpring products are expected to be available for sale in the US, via IDT's appointed distributor ANI Pharmaceuticals, in CYH2 2016.

This work is partially supported by the fund raising undertaken by the Company in Dec 2015.

ENDS

For further information please contact:
IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. IDT is commercializing a portfolio of 24 generic drugs to manufacture and sell via US distribution partners. The company is also exploring EU and Japanese sales opportunities. With IDT's 2013 temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class

facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based at the Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.

About WellSpring Pharma Services

WellSpring is a full-service CDMO which has the industry's respect for providing turn-key supply chain solutions for pharmaceutical products since 2001. Services include technology transfer and process optimization of oral solids (tablets and capsules), semi-solids (creams, lotions, shampoos and gels) and non-sterile liquids. WellSpring's goal is to forge long-term relationships by developing effective programs that will reduce your supply chain costs and ensure high standards of customer service.

For personal use only